ARS Pharmaceuticals, Inc. SPRY Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Net margin | -200%+3.2pp | -203.3%-147pp | -56.1%-13.3pp | -42.7%-26.6pp | -16.1%-25.1pp | |
| Returns | ||||||
| Return on equity | -136.4%-44.1pp | -92.3%-46.4pp | -45.9%-22.4pp | -23.6%-16.7pp | -6.9%-10.2pp | |
| Return on invested capital | -125.5%-29.8pp | -95.6%-17.3pp | -78.3%-13.2pp | -65%-24.6pp | -40.4%-15.0pp | |
| Efficiency | ||||||
| Asset turnover | 0.3×+0.1× | 0.2×-0.2× | 0.5×+0.1× | 0.4×+0.1× | 0.4×0.0× | |
| Liquidity | ||||||
| Current ratio | 4.9×-2.3× | 7.3×+0.6× | 6.7×+0.5× | 6.2×-4.8× | 11×-3.3× | |
| Leverage | ||||||
| Debt-to-equity | 1.6×+0.7× | 0.8×+0.2× | 0.7×+0.7× | 0×0.0× | 0×0.0× | |
| Per Share | ||||||
| Book value per share | $0.62-46.7% | $1.16-22.4% | $1.49-23.6% | $1.96-16.3% | $2.34-6.9% | |
| Valuation | ||||||
| Market capitalization | $1.05B-48.7% | $1.15B+15.9% | $993.2M-39.7% | $1.65B+33.5% | $1.23B+20.4% | |
| Price / sales | 10.6×-10.4× | 13.7×+6.7× | 7×-7.7× | 14.7×+2.0× | 12.7×+1.2× | |
| Price / book | 13×+6.2× | 10.1×+3.4× | 6.7×-1.8× | 8.6×+3.2× | 5.4×+1.4× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do ARS Pharmaceuticals, Inc.'s ratios come from?
- Every ratio is computed from ARS Pharmaceuticals, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
